Exenatide is Non-inferior to Insulin in Reducing HbA1c: An Integrated Analysis of 1423 Patients with Type 2 Diabetes

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland

(2011) M. Brändle et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

(2009) T. Okerson et al.   AMERICAN JOURNAL OF HYPERTENSION

Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006

(2009) Bernard M.Y. Cheung et al.   AMERICAN JOURNAL OF MEDICINE

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine

(2009) Rosalind Fabunmi et al.   CURRENT MEDICAL RESEARCH AND OPINION

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Standards of Medical Care in Diabetes--2009

(2009)   DIABETES CARE

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting

(2009) T. Mittendorf et al.   DIABETES OBESITY & METABOLISM

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

(2009) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Diabetes medications and body weight

(2009) Joanna Mitri et al.   Expert Opinion On Drug Safety

Intensive versus Conventional Glucose Control in Critically Ill Patients

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

(2008) Anette Woehl et al.   Cardiovascular Diabetology

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial

(2008) M. Davies et al.   DIABETES OBESITY & METABOLISM

Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients

(2008) K. Eeg-Olofsson et al.   DIABETOLOGIA

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE